4.7 Review

Mesenchymal stem cell-derived exosome: A tumor regulator and carrier for targeted tumor therapy

Journal

CANCER LETTERS
Volume 526, Issue -, Pages 29-40

Publisher

ELSEVIER IRELAND LTD
DOI: 10.1016/j.canlet.2021.11.015

Keywords

Mesenchymal stem cells; Immunomodulatory; Tumor associated MSCs-derived exosomes; Drug delivery; Targeted tumor therapy

Categories

Funding

  1. National Natural Science Foundation of China [81672877, 82173194]
  2. Key research project of Liaoning Provincial Department of Education of China [ZD2020004]

Ask authors/readers for more resources

MSCs-Exo play a significant role in tumor growth and have the potential to be safe carriers for anti-tumor drugs. Despite the controversial relationship between MSCs-Exo and tumors, they show promise in targeted tumor therapy.
Mesenchymal stem cells (MSCs) are multipotent stromal cells that have the ability to differentiate into multiple cell types. Several studies have shown that exosomes secreted by MSCs (MSCs-Exo) play an important role in tumor growth, angiogenesis, invasion, and drug resistance. However, contradictory results have suggested that MSCs-Exo can also suppress tumors through specific mechanisms, such as regulating immune responses and intercellular signaling. Consequently, the relationship between MSCs-Exo and tumors remains controversial. However, it is undeniable that exosomes, as natural vesicles, can be excellent drug carriers and show promise for application in targeted tumor therapy. Here, we review the current knowledge regarding the involvement of MSCs-Exo in tumor progression and their potential as drug delivery systems in targeted therapy. We argue that MSCs-Exo can be used as safe carriers of antitumor drugs.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available